Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Expanded Clinical Study Evaluating the AAV2-RPE65 Gene Therapy (LX101) in Patients With Leber's Congenital Amaurosis (LCA)

NCT06024057 is registered in ClinicalTrials.gov with Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine as lead sponsor.

NCT NCT06024057
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06024057 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Expanded Clinical Study Evaluating the AAV2-RPE65 Gene Therapy (LX101) in Patients With Leber's Congenital Amaurosis (LCA)
Lead sponsor
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase
Not applicable
Overall status
Not yet recruiting
Start date
September 1, 2023
Completion date
September 30, 2038
Enrollment
3 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

to evaluate the scaling clinical study of aav2-rpe65 gene therapy agent (lx101) in patients with congenital amaurosis (lca)